Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 2Tumor-Agnostic 1

Conditions

Leiomyosarcoma 2Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × PTC596 × Clear all
NCT05269355 2025-06-13

SUNRISELMS

PTC Therapeutics

Phase 2/3 Terminated
359 enrolled 15 charts
Sarcoma

Leiomyosarcoma

NCT03761095 2024-03-15

A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

PTC Therapeutics

Phase 1 Completed
41 enrolled
Sarcoma

Leiomyosarcoma

NCT02404480 2017-12-08

PTC596 in Patients With Advanced Solid Tumors

PTC Therapeutics

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡